Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.
Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N. Sade-Feldman M, et al. Among authors: jenkins rw. Cell. 2018 Nov 1;175(4):998-1013.e20. doi: 10.1016/j.cell.2018.10.038. Cell. 2018. PMID: 30388456 Free PMC article.
N-MYC impairs innate immune signaling in high-grade serous ovarian carcinoma.
Miranda A, Pattnaik S, Hamilton PT, Fuss MA, Kalaria S, Laumont CM, Smazynski J, Mesa M, Banville A, Jiang X, Jenkins R, Cañadas I, Nelson BH. Miranda A, et al. Sci Adv. 2024 May 17;10(20):eadj5428. doi: 10.1126/sciadv.adj5428. Epub 2024 May 15. Sci Adv. 2024. PMID: 38748789 Free PMC article.
Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial.
Mooradian MJ, Fintelmann FJ, LaSalle TJ, Simon J, Graur A, Muzikansky A, Mino-Kenudson M, Shalhout S, Kaufman HL, Jenkins RW, Lawrence D, Lawless A, Sharova T, Uppot RN, Fang J, Blaum EM, Gonye ALK, Gushterova I, Boland GM, Azzoli C, Hacohen N, Sade-Feldman M, Sullivan RJ. Mooradian MJ, et al. Among authors: jenkins rw. Nat Commun. 2024 Aug 27;15(1):7357. doi: 10.1038/s41467-024-51722-x. Nat Commun. 2024. PMID: 39191779 Free PMC article. Clinical Trial.
Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States.
Kim JW, Abudayyeh OO, Yeerna H, Yeang CH, Stewart M, Jenkins RW, Kitajima S, Konieczkowski DJ, Medetgul-Ernar K, Cavazos T, Mah C, Ting S, Van Allen EM, Cohen O, Mcdermott J, Damato E, Aguirre AJ, Liang J, Liberzon A, Alexe G, Doench J, Ghandi M, Vazquez F, Weir BA, Tsherniak A, Subramanian A, Meneses-Cime K, Park J, Clemons P, Garraway LA, Thomas D, Boehm JS, Barbie DA, Hahn WC, Mesirov JP, Tamayo P. Kim JW, et al. Among authors: jenkins rw. Cell Syst. 2017 Aug 23;5(2):105-118.e9. doi: 10.1016/j.cels.2017.08.002. Cell Syst. 2017. PMID: 28837809 Free PMC article.
Mechanisms of resistance to immune checkpoint inhibitors.
Jenkins RW, Barbie DA, Flaherty KT. Jenkins RW, et al. Br J Cancer. 2018 Jan;118(1):9-16. doi: 10.1038/bjc.2017.434. Epub 2018 Jan 2. Br J Cancer. 2018. PMID: 29319049 Free PMC article. Review.
Mechanisms of Resistance to Immune Checkpoint Blockade.
Liu D, Jenkins RW, Sullivan RJ. Liu D, et al. Among authors: jenkins rw. Am J Clin Dermatol. 2019 Feb;20(1):41-54. doi: 10.1007/s40257-018-0389-y. Am J Clin Dermatol. 2019. PMID: 30259383 Free PMC article. Review.
Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade.
Sehgal K, Portell A, Ivanova EV, Lizotte PH, Mahadevan NR, Greene JR, Vajdi A, Gurjao C, Teceno T, Taus LJ, Thai TC, Kitajima S, Liu D, Tani T, Noureddine M, Lau CJ, Kirschmeier PT, Liu D, Giannakis M, Jenkins RW, Gokhale PC, Goldoni S, Pinzon-Ortiz M, Hastings WD, Hammerman PS, Miret JJ, Paweletz CP, Barbie DA. Sehgal K, et al. Among authors: jenkins rw. J Clin Invest. 2021 Jan 19;131(2):e135038. doi: 10.1172/JCI135038. J Clin Invest. 2021. PMID: 33151910 Free PMC article.
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.
Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, Sorrentino JA, Bisi JE, Lizotte PH, Merlino AA, Quinn MM, Bufe LE, Yang A, Zhang Y, Zhang H, Gao P, Chen T, Cavanaugh ME, Rode AJ, Haines E, Roberts PJ, Strum JC, Richards WG, Lorch JH, Parangi S, Gunda V, Boland GM, Bueno R, Palakurthi S, Freeman GJ, Ritz J, Haining WN, Sharpless NE, Arthanari H, Shapiro GI, Barbie DA, Gray NS, Wong KK. Deng J, et al. Among authors: jenkins rw. Cancer Discov. 2018 Feb;8(2):216-233. doi: 10.1158/2159-8290.CD-17-0915. Epub 2017 Nov 3. Cancer Discov. 2018. PMID: 29101163 Free PMC article.
Targeting TANK-binding kinase 1 (TBK1) in cancer.
Revach OY, Liu S, Jenkins RW. Revach OY, et al. Among authors: jenkins rw. Expert Opin Ther Targets. 2020 Nov;24(11):1065-1078. doi: 10.1080/14728222.2020.1826929. Epub 2020 Oct 5. Expert Opin Ther Targets. 2020. PMID: 32962465 Free PMC article. Review.
77 results